Kumar A, Lunawat A, Kumar A, Sharma T, Islam M, Kahlon M
AAPS PharmSciTech. 2024; 25(3):55.
PMID: 38448649
DOI: 10.1208/s12249-024-02765-2.
Sati P, Sharma E, Dhyani P, Attri D, Rana R, Kiyekbayeva L
Eur J Med Res. 2024; 29(1):90.
PMID: 38291541
PMC: 10826257.
DOI: 10.1186/s40001-024-01657-2.
Wu C, Murakami M, Li Y, Huang Y, Chang Y, Hung T
Pharmaceuticals (Basel). 2023; 16(11).
PMID: 38004460
PMC: 10674403.
DOI: 10.3390/ph16111595.
Yun W, Kim J, Jin Y, Roh Y, Song H, Seol A
Lab Anim Res. 2023; 39(1):23.
PMID: 37864254
PMC: 10588074.
DOI: 10.1186/s42826-023-00175-2.
Skinner K, Palkar A, Hong A
Cancers (Basel). 2023; 15(17).
PMID: 37686513
PMC: 10487083.
DOI: 10.3390/cancers15174236.
ABCB1 and ABCG2 Overexpression Mediates Resistance to the Phosphatidylinositol 3-Kinase Inhibitor HS-173 in Cancer Cell Lines.
Wu C, Hung C, Hsieh Y, Murakami M, Huang Y, Su T
Cells. 2023; 12(7).
PMID: 37048130
PMC: 10093605.
DOI: 10.3390/cells12071056.
HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies.
Pasqua A, Sharp S, Chessum N, Hayes A, Pellegrino L, Tucker M
J Med Chem. 2023; 66(8):5907-5936.
PMID: 37017629
PMC: 10150365.
DOI: 10.1021/acs.jmedchem.3c00156.
Histoblot: A sensitive method to quantify the expression of proteins in normal and pathological conditions.
Aguado C, Martin-Belmonte A, Alfaro-Ruiz R, Martinez-Moreno A, Lujan R
Histol Histopathol. 2023; 38(7):725-737.
PMID: 36648032
DOI: 10.14670/HH-18-581.
Hydroxygenkwanin Improves the Efficacy of Cytotoxic Drugs in ABCG2-Overexpressing Multidrug-Resistant Cancer Cells.
Li Y, Murakami M, Huang Y, Hung T, Wang S, Wu Y
Int J Mol Sci. 2022; 23(21).
PMID: 36361555
PMC: 9658017.
DOI: 10.3390/ijms232112763.
MYC and therapy resistance in cancer: risks and opportunities.
Donati G, Amati B
Mol Oncol. 2022; 16(21):3828-3854.
PMID: 36214609
PMC: 9627787.
DOI: 10.1002/1878-0261.13319.
The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs.
Wu C, Murakami M, Wu Y, Lin C, Li Y, Huang Y
Biomed Pharmacother. 2022; 149:112922.
PMID: 36068781
PMC: 10506422.
DOI: 10.1016/j.biopha.2022.112922.
Clinical and biological impact of ATP-binding cassette transporter activity in adult acute myeloid leukemia.
Sourdeau E, Suner L, Memoli M, Genthon A, Feger F, Soret L
Haematologica. 2022; 108(1):61-68.
PMID: 35924580
PMC: 9827156.
DOI: 10.3324/haematol.2022.280676.
Curcumin Induces Apoptosis of Chemoresistant Lung Cancer Cells via ROS-Regulated p38 MAPK Phosphorylation.
Wu M, Huang Y, Chiu L, Cherng S, Sheu G, Yang T
Int J Mol Sci. 2022; 23(15).
PMID: 35897820
PMC: 9367815.
DOI: 10.3390/ijms23158248.
Activation of the integrated stress response is a vulnerability for multidrug-resistant FBXW7-deficient cells.
Sanchez-Burgos L, Navarro-Gonzalez B, Garcia-Martin S, Sirozh O, Mota-Pino J, Fueyo-Marcos E
EMBO Mol Med. 2022; 14(9):e15855.
PMID: 35861150
PMC: 9449593.
DOI: 10.15252/emmm.202215855.
From Therapy Resistance to Targeted Therapies in Prostate Cancer.
Moreira-Silva F, Henrique R, Jeronimo C
Front Oncol. 2022; 12:877379.
PMID: 35686097
PMC: 9170957.
DOI: 10.3389/fonc.2022.877379.
Emerging consensus on the mechanism of polyspecific substrate recognition by the multidrug transporter P-glycoprotein.
Xia D, Zhou F, Esser L
Cancer Drug Resist. 2022; 2(3):471-489.
PMID: 35582581
PMC: 8992534.
DOI: 10.20517/cdr.2019.22.
P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhiitor Ensartinib in Cancer Cells.
Wu C, Hung C, Murakami M, Wu Y, Lin C, Huang Y
Cancers (Basel). 2022; 14(9).
PMID: 35565470
PMC: 9104801.
DOI: 10.3390/cancers14092341.
Gastrointestinal cancer drug resistance: the role of exosomal miRNAs.
Salehi M, Vafadar A, Khatami S, Taheri-Anganeh M, Vakili O, Savardashtaki A
Mol Biol Rep. 2021; 49(3):2421-2432.
PMID: 34850336
DOI: 10.1007/s11033-021-07007-3.
The Second-Generation PIM Kinase Inhibitor TP-3654 Resensitizes ABCG2-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs.
Wu C, Li Y, Chi Y, Huang Y, Hung T, Wu Y
Int J Mol Sci. 2021; 22(17).
PMID: 34502348
PMC: 8431370.
DOI: 10.3390/ijms22179440.
Branebrutinib (BMS-986195), a Bruton's Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents.
Wu C, Murakami M, Wu Y, Chi Y, Hsiao S, Huang Y
Front Cell Dev Biol. 2021; 9:699571.
PMID: 34350184
PMC: 8326665.
DOI: 10.3389/fcell.2021.699571.